Citations

Clear

1422 citation(s) found for "White, M".

Biomarkers of cellular senescence and risk of death in humans
Weston, Susan A., Atkinson, Elizabeth J. , Gree, Michaela E. Mc, White, Thomas A. , Heeren, Amanda A., Rocca, Walter A. , Palmer, Allyson K. , Cummings, Steven R. , Fielding, Roger A. , St Sauver, Jennifer L , Mc Gree, Michaela E, Palmer, Allyson K , Bielinski, Suzette J. , LeBrasseur, Nathan K , Sauver, Jennifer L. St. , Mielke, Michelle M. , Olson, Janet E. , LeBrasseur, Nathan K.

Mayo Clinic

Aging Cell | October 8, 2023 | Volume: 22 | Issue: 12 | Pages: No page available

10.1111/acel.14006 | PMID 37803875 Get It

AbstractA robust and heterogenous secretory phenotype is a core feature of most senescent cells. In addition to mediators of age‐related pathology, components of the senescence associated secretory phenotype (SASP) have been studied as biomarkers of senescent cell burden and, in turn, biological age. Therefore, we hypothesized that circulating concentrations of candidate senescence biomarkers, including chemokines, cytokines, matrix remodeling proteins, and growth factors, could predict mortality in older adults. We assessed associations between plasma levels of 28 SASP proteins and risk of mortality over a median follow‐up of 6.3 years in 1923 patients 65 years of age or older with zero or one chronic condition at baseline. Overall, the five senescence biomarkers most strongly associated with an increased risk of death were GDF15, RAGE, VEGFA, PARC, and MMP2, after adjusting for age, sex, race, and the presence of one chronic condition. The combination of biomarkers and clinical and demographic covariates exhibited a significantly higher c‐statistic for risk of death (0.79, 95% confidence interval (CI): 0.76–0.82) than the covariates alone (0.70, CI: 0.67–0.74) (p < 0.001). Collectively, these findings lend further support to biomarkers of cellular senescence as informative predictors of clinically important health outcomes in older adults, including death.
Breast-Density Semantic Segmentation with Probability Scaling for BI-RADS Assessment using DeepLabV3
Testagrose, Conrad , Gupta, Vikash , Erdal, Barbaros S. , White, Richard D. , Maxwell, Robert W. , Liu, Xudong , Kahanda, Indika , Elfayoumy, Sherif , Klostermeyer, William F. , Demirer, Mutlu , White, Richard D , Erdal, Barbaros S , Demirer, Mutlu , Gupta, Vikash

Mayo Clinic

Proceedings of the 14th ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics | October 4, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.1145/3584371.3612983 Get It

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
Rivero, Jaydira Del , Perez, Kimberly , Kennedy, Erin B. , Mittra, Erik , Vijayvergia, Namrata , Arshad, Junaid , Basu, Sandip , Chauhan, Aman , Dasari, Arvind , Bellizzi, Andrew M. , Gangi, Alexandra , Grady, Erin , Ivanidze, Jana , Lewis, Mark A. , Mailman, Josh , Raj, Nitya , White, Sarah B. , Chan, Jennifer A. , Kunz, Pamela L. , Singh, Simron , Bergsland, Emily K. , Del Rivero, Jaydira , Dasari, Arvind N , Howe, James R , Raj, Nitya , Soares, Heloisa P , Soulen, Michael C , Kunz, Pamela L , Singh, Simron , Halfdanarson, Thorvardur R , Strosberg, Jonathan R , Bergsland, Emily K , Chauhan, Aman , Bellizzi, Andrew M , Vijayvergia, Namrata , Arshad, Junaid , Howe, James R. , Soares, Heloisa P. , Hálfdánarson, Þorvarður R. , Strosberg, Jonathan

Mayo Clinic

Journal of Clinical Oncology | September 29, 2023 | Volume: 41 | Issue: 32 | Pages: 5049-5067

10.1200/jco.23.01529 | PMID 37774329 Get It

PURPOSE To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). METHODS ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS Eight randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS Somatostatin analogs (SSAs) are recommended as first-line systemic therapy for most patients with G1-grade 2 (G2) metastatic well-differentiated GI-NETs. Observation is an option for patients with low-volume or slow-growing disease without symptoms. After progression on SSAs, peptide receptor radionuclide therapy (PRRT) is recommended as systematic therapy for patients with somatostatin receptor (SSTR)–positive tumors. Everolimus is an alternative second-line therapy, particularly in nonfunctioning NETs and patients with SSTR-negative tumors. SSAs are standard first-line therapy for SSTR-positive pancreatic (pan)NETs. Rarely, observation may be appropriate for asymptomatic patients until progression. Second-line systemic options for panNETs include PRRT (for SSTR-positive tumors), cytotoxic chemotherapy, everolimus, or sunitinib. For SSTR-negative tumors, first-line therapy options are chemotherapy, everolimus, or sunitinib. There are insufficient data to recommend particular sequencing of therapies. Patients with G1-G2 high-volume disease, relatively high Ki-67 index, and/or symptoms related to tumor growth may benefit from early cytotoxic chemotherapy. For G3 GEP-NETs, systemic options for G1-G2 may be considered, although cytotoxic chemotherapy is likely the most effective option for patients with tumor-related symptoms, and SSAs are relatively ineffective. Qualifying statements are provided to assist with treatment choice. Multidisciplinary team management is recommended, along with shared decision making with patients, incorporating their values and preferences, potential benefits and harms, and other characteristics and circumstances, such as comorbidities, performance status, geographic location, and access to care. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
Lee, Yoo Jin , Li, Dalin , Debbas, Philip , Hampton, Melissa, Ebinger, Joseph E. , Chiorean, Michael , Lum, Donald , Damas, Oriana M. , Melmed, Gil , Group, CORALE-IBD Study, Banty, Andrea, Feldman, Edward J., Ha, Christina , Lee, Susie, Rabizadeh, Shervin , Stein, Theodore , Solomon, Theodore, Syal, Gaurav , Targan, Stephan R. , Vasiliauskas, Eric, Ziring, David , Bonthala, Niru, Botwin, Gregory S, Khanishian, Elizabeth, Pozdnyakova, Valeriya , Gu, Phillip , White, Shane , Zamudio, Cindy, Gonzalez, Daniel , Parry, Alyssa, Hanna, Mary , Chan, Justin, Ebinger, Joe , Wu, Min , Hoang, Amy, Wynter, Timothy , Sun, Nancy , Figueiredo, Jane C. , Merchant, Akil , Merin, Noah , Appel, Keren , Boland, Brigid S. , Charabaty, Aline , Cohen, Erica , Flynn, Ann D. , Valentine, John F. , Ehrlich, Adam C., Fudman, David , Horizon, Arash, Karayev, Dmitry, Kretzmann, Benjamin, Hou, Jason K. , Hwang, Caroline, Lazarev, Mark , Fausel, Rebecca, Reddy, Swapna , McConnell, Ryan , Mattar, Mark , Metwally, Mark, Ostrov, Arthur, Parekh, Nimisha, Raffals, Laura H., Sheibani, Sarah , Younes, Ziad , Braun, Jonathan , Melmed, Gil Y , Mujukian, Angela , Mengesha, Emebet , Cheng, Susan , McGovern, Dermot , Group, CORALE-IBD Study, Botwin, Gregory J., White, Shane, Joung, Sandy , Hoang, Amy, Reckamp, Karen L. , Kumar, Rashmi , Rubin, David T. , Siegel, Corey A , Wolf, Douglas C.

Mayo Clinic

Inflammatory Bowel Diseases | September 29, 2023 | Volume: 30 | Issue: 8 | Pages: 1430-1434

10.1093/ibd/izad198 | PMID 37773982 Get It

A new test method for biochemical analysis of plasmalogens in dried blood spots and erythrocytes from patients with peroxisomal disorders
Wegwerth, Peter J, White, Amy , Stoway, Stephanie D., Loken, Perry R , Oglesbee, Devin , Matern, Dietrich , Tortorelli, Silvia , Raymond, Kimiyo , Gavrilov, Dimitar K. , White, Amy L , Raymond, Kimiyo M, Oglesbee, Devin , Braverman, Nancy

Mayo Clinic

Journal of Inherited Metabolic Disease | September 25, 2023 | Volume: 46 | Issue: 6 | Pages: 1159-1169

10.1002/jimd.12682 | PMID 37747296 Get It

AbstractMeasurement of plasmalogens is useful for the biochemical diagnosis of rhizomelic chondrodysplasia punctata (RCDP) and is also informative for Zellweger spectrum disorders (ZSD). We have developed a test method for the simultaneous quantitation of C16:0, C18:0, and C018:1 plasmalogen (PG) species and their corresponding fatty acids (FAs) in dried blood spots (DBS) and erythrocytes (RBC) by using capillary gas chromatography–mass spectrometry. Normal reference ranges for measured markers and 10 calculated ratios were established by the analysis of 720 and 473 unaffected DBS and RBC samples, respectively. Determination of preliminary disease ranges was made by using 45 samples from 43 unique patients: RCDP type 1 (DBS: 1 mild, 17 severe; RBC: 1 mild, 6 severe), RCDP type 2 (DBS: 2 mild, 1 severe; RBC: 2 severe), RCDP type 3 (DBS: 1 severe), RCDP type 4 (RBC: 2 severe), and ZSD (DBS: 3 severe; RBC: 2 mild, 7 severe). Postanalytical interpretive tools in Collaborative Laboratory Integrated Reports (CLIR) were used to generate an integrated score and a likelihood of disease. In conjunction with a review of clinical phenotype, phytanic acid, and very long‐chain FA test results, the CLIR analysis allowed for differentiation between RCDP and ZSD. Data will continue to be gathered to improve CLIR analysis as more samples from affected patients with variable disease severity are analyzed. The addition of DBS analysis of PGs may allow for at‐home specimen collection and second‐tier testing for newborn screening programs.
Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy
Lin, Heather , Diego, Emilia J. , Yang, Wei , Valero, Vicente , Mitchell, Melissa P. , White, Richard L. , Rauch, Gaiane M., Kuerer, Henry M. , Group, Exceptional Responders Study, Moseley, Tanya W. , Leung, Jessica WT, Huang, Monica L. , Arribas, Elsa , Parra, Raquel FD van la, Teshome, Mediget , Hwang, Rosa F. , Miggins, Makesha, Piotrowski, Matthew J., Refinetti, Ana P, Ehlers, Richard A., Colen, Jessica Suarez, Loveland‐Jones, Catherine, Lesnikowski, Beth Ann, Samiian, Laila, Chong, Clayton, Arribas, Elsa M , Johnson, Helen Margaret , Shen, Yu , Krishnamurthy, Savitri , Smith, Benjamin D. , Lucci, Anthony , Sun, Susie X. , Shaitelman, Simona Flora , Boughey, Judy C. , Rauch, Gaiane M. , Group, Exceptional Responders Study, Candelaria, Rosalind P. , Adrada, Beatriz E. , Hunt, Kelly K. , Bedrosian, Isabelle

Mayo Clinic

JAMA Network Open | September 14, 2023 | Volume: 6 | Issue: 9 | Pages: e2333933

10.1001/jamanetworkopen.2023.33933 | PMID 37707811 Get It

ImportancePatients should have an active role in decisions about pursuing or forgoing specific therapies in treatment de-escalation trials.ObjectiveTo evaluate longitudinal patient-reported outcomes (PROs) encompassing decisional comfort and health-related quality of life (HRQOL) among patients who elected to enroll in a clinical trial evaluating radiotherapy alone, without breast surgery, for invasive breast cancers with exceptional response to neoadjuvant systemic therapy (NST).Design, Setting, and ParticipantsProspective, single-group, phase 2 clinical trial at 7 US medical centers. Women aged 40 years or older with invasive cT1-2 N0-1 M0 triple-negative or human epidermal growth factor receptor 2 (ERBB2)–positive breast cancer with no pathologic evidence of residual disease following standard NST enrolled from March 6, 2017, to November 9, 2021. Validated PRO measures were administered at baseline and 6, 12, and 36 months post-radiotherapy. Data were analyzed from January to February 2023.InterventionsPRO measures included the Decision Regret Scale (DRS), Functional Assessment of Cancer Therapy—Lymphedema (FACT-B+4), and Breast Cancer Treatment Outcomes Scale (BCTOS).Main Outcomes and MeasuresChanges in PRO measure scores and subscores over time.ResultsAmong 31 patients, the median (IQR) age was 61 (56-66) years, 26 (84%) were White, and 26 (84%) were non-Hispanic. A total of 15 (48%) had triple-negative disease and 16 (52%) had ERBB2-positive disease. Decisional comfort was high at baseline (median [IQR] DRS score 10 [0-25] on a 0-100 scale, with higher scores indicating higher decisional regret) and significantly increased over time (median [IQR] DRS score at 36 months, 0 [0-20]; P &amp;lt; .001). HRQOL was relatively high at baseline (median [IQR] FACT-B composite score 121 [111-134] on a 0-148 scale, with higher scores indicating higher HRQOL) and significantly increased over time (median [IQR] FACT-B score at 36 months, 128 [116-137]; P = .04). Perceived differences between the affected breast and contralateral breast were minimal at baseline (median [IQR] BCTOS score 1.05 [1.00-1.23] on a 1-4 scale, with higher scores indicating greater differences) and increased significantly over time (median [IQR] BCTOS score at 36 months, 1.36 [1.18-1.64]; P &amp;lt; .001). At 36 months postradiotherapy, the cosmetic subscore was 0.45 points higher than baseline (95% CI, 0.16-0.74; P = .001), whereas function, pain, and edema subscores were not significantly different than baseline.Conclusions and RelevanceIn this nonrandomized phase 2 clinical trial, analysis of PROs demonstrated an overall positive experience for trial participants, with longitudinal improvements in decisional comfort and overall HRQOL over time and minimal lasting adverse effects of therapy.Trial RegistrationClinicalTrials.gov Identifier: NCT02945579
Physical Resilience as a Predictor of Lifespan and Late-Life Health in Genetically Heterogeneous Mice
Brown, Ashley K. , Mazula, Daniel L., Roberts, Lori, Roos, Carolyn M, Pearsall, Vesselina, Schafer, Marissa , White, Thomas A. , Huang, Runqing, Kumar, Navasuja , Miller, Richard A. , Roos, Carolyn, Pearsall, Vesselina M, Miller, Jordan D. , Schafer, Marissa J , Zhang, Bin , LeBrasseur, Nathan K.

Mayo Clinic

The Journals of Gerontology: Series A | September 13, 2023 | Volume: 79 | Issue: 1 | Pages: No page available

10.1093/gerona/glad207 | PMID 37701988 Get It

Abstract Dynamic measures of resilience—the ability to resist and recover from a challenge—may be informative of the rate of aging before overt manifestations such as chronic disease, disability, and frailty. From this perspective mid-life resilience may predict longevity and late-life health. To test this hypothesis, we developed simple, reproducible, clinically relevant challenges, and outcome measures of physical resilience that revealed differences between and within age groups of genetically heterogeneous mice, and then examined associations between mid-life resilience and both lifespan and late-life measures of physiological function. We demonstrate that time to recovery from isoflurane anesthesia and weight change following a regimen of chemotherapy significantly differed among young, middle-aged, and older mice, and were more variable in older mice. Females that recovered faster than the median time from anesthesia (more resilient) at 12 months of age lived 8% longer than their counterparts, while more resilient males in mid-life exhibited better cardiac (fractional shortening and left ventricular volumes) and metabolic (glucose tolerance) function at 24 months of age. Moreover, female mice with less than the median weight loss at Day 3 of the cisplatin challenge lived 8% longer than those that lost more weight. In contrast, females who had more weight loss between Days 15 and 20 were relatively protected against early death. These data suggest that measures of physical resilience in mid-life may provide information about individual differences in aging, lifespan, and key parameters of late-life health.
OS09.5.A BREAKING DOWN BARRIERS: THE IMPACT OF BLOOD-BRAIN BARRIER DISRUPTION ON THE GLIOMA METABOLIC MICROENVIRONMENT, IN SITU
Riviere-Cazaux, Cécile , Carlstrom, Luke, Munoz-Casabella, Amanda , Gharibi-Loron, Ali, Brown, Dennis , Miller, Kai J. , White, J. Courtland, Himes, Brent, Jusué-Torres, Ignacio , Ikram, S. , Hirte, Renee, Oh, Ju-Hee, Elmquist, William F. , Vaubel, Rachel, Warrington, A.P., Kizilbash, Sani H. , Kizilbash, Sani H , Jusue-Torres, Ignacio , Carlstrom, L, Rajani, Karishma , Rahman, Masum , Brown, D, Ikram, S, Ransom, S. M. , Sarkaria, Jann N. , Rodriguez, Moses , Warrington, A, Burns, Terry C.

Mayo Clinic

Neuro-Oncology | September 8, 2023 | Volume: 25 | Issue: Supplement_2 | Pages: ii21-ii21

10.1093/neuonc/noad137.062 Get It

Abstract BACKGROUND The microenvironment of glioblastoma is complex and defined in part by protumorigenic metabolic changes. Within this microenvironment, blood-brain barrier disruption is often associated with the most aggressive portions of the tumor. To date, the metabolic tumor microenvironments of enhancing, blood-brain barrier (BBB) disrupted portions of gliomas, as compared to BBB-intact tumor, remain poorly understood. Specifically, it is unclear if the associated blood-brain barrier disruption merely reflects or functionally supports tumor aggressiveness. METHODS Intra-operative high-molecular weight microdialysis was utilized under an investigational device exemption (NCT NCT04047264) to sample the extracellular metabolome of radiographically diverse regions during fifteen neurosurgical resections. The global extracellular metabolome of recovered microdialysate from contrast-enhancing and non-enhancing tumor, as well as brain adjacent to tumor, was evaluated via ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) on the Metabolon platform and assessed using enrichment and correlation analyses. RESULTS Among 162 named metabolites identified via ultra-performance liquid chromatography tandem mass spectrometry, a novel glioma-associated metabolite, guanidinoacetate (GAA), was 126.32x higher in enhancing tumor than in adjacent brain and 13.63x higher in non-enhancing tumor than brain. Forty-eight additional metabolites were 2.05-10.18x more abundant in enhancing tumor than brain, including carnitine family members and all nine large neutral amino acids. Except for GAA and 2-hydroxyglutarate in IDH-mutant gliomas, differences between non-enhancing tumor and brain microdialysate were comparatively modest and less consistent, suggesting heterogeneity in the glioma metabolic microenvironment of blood-brain barrier (BBB) intact areas as compared to BBB-disrupted portions of gliomas. Interestingly, the enhancing but not the non-enhancing glioma metabolome was significantly enriched for plasma-associated metabolites, largely comprising amino acids and carnitines. CONCLUSION Our patient-derived data suggest that the BBB-disrupted metabolome of high-grade gliomas is characterized by metabolite diffusion from circulation into the tumor microenvironment. Further studies are ongoing to determine how this alteration in the glioma extracellular metabolome impacts glioma behavior and how it could be therapeutically targeted via BBB-modulating drugs.
Hemicord White Matter Enhancement and the Croissant Sign in Cervical Spondylotic Myelopathy
Li, Xiaoyang , Krecke, Karl N. , Weinshenker, Brian G. , Ζεκερίδου, Αναστασία , Toledano, Michel , Weinshenker, Brian G , Clarke, Michelle J. , Flanagan, Eoin P.

Mayo Clinic

Neurology | August 30, 2023 | Volume: 101 | Issue: 21 | Pages: 968-969

10.1212/wnl.0000000000207793 | PMID 37648534 Get It

Significant Variability in Postoperative Thromboprophylaxis in Cushing's Disease Patients: A Survey of the North American Skull Base Society and the AANS/CNS Joint Tumor Section
White, Alexandra J. , Yogi-Morren, Divya , Kshettry, Varun R. , Recinos, Pablo F , Kshettry, Varun R , Almeida, João Paulo , Petitt, Jordan C. , Recinos, Pablo F.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | August 29, 2023 | Volume: 85 | Issue: 05 | Pages: 540-545

10.1055/s-0043-1772698 | PMID 39228887 Get It

Abstract Introduction Cushing's disease (CD) is associated with hypercoagulability which is associated with an increased risk of venous thromboembolic events (VTEs) perioperatively. This risk persists even after successful transsphenoidal surgery (TSS). However, there are no current guidelines for pharmacologic thromboprophylaxis in this patient population. Objective Characterize existing thromboprophylaxis management practices in patients undergoing TSS for CD. Methods An anonymous RedCap survey comprised of questions about perioperative thromboprophylaxis in CD patients was distributed via the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Joint Tumor Section and the North American Skull Base Society (NASBS) email lists. Results The survey was distributed to 554 members of the AANS/CNS Joint Tumor Section and 1,094 members of NASBS asking that members who surgically treat CD respond. Sixty responses (3.0% response rate) were received. Fifty-two (86.7%) respondents are involved in the postoperative management of CD patients. Thirty-six (69.2%) treat all patients with postoperative VTE chemoprophylaxis, 8 (15.4%) treat some patients, while 8 (15.4%) do not use chemoprophylaxis. Preferred chemoprophylaxis varies as 26 (59.1%) administer low molecular weight heparin, 14 (31.8%) give unfractionated heparin, 1 (2.3%) give direct oral anticoagulants, and 3 (6.8%) give aspirin. Most (28, 53.8%) of the respondents perceive the VTE risk in this patient population to be 0 to 5%, 16 (30.8%) perceive the risk to be 6 to 10%, and 8 (15.4%) perceive it to be 11 to 20%. Conclusion There is great variability in VTE detection and postoperative prevention practice patterns in CD patients. This study highlights the need for prospective studies to clarify optimal pharmacologic chemoprophylaxis strategies and duration in this patient population.